Cara Therapeutics Inc. 
CR845-CLIN3101 
26 Apr2019 Confidential Page 5 of58 
5.Continues to experience chronic kidney disease-associated
pruritus since the previous study (ie, CR845-CLIN2005
[Part BJ or CR845-CLIN2101 [Part A]); de novo patients
experiencing chronic kidney disease-associated pruritus at the
time of Screening
6.If female:
a.Is not of childbearing potential (surgically sterile or
postmenopausal, as defined in Section [IP_ADDRESS]); or
b.Has a negative serum pregnancy test at screening and
agrees to use acceptable contraceptive measures ( as
defined in Section [IP_ADDRESS]) from the time of informed
consent until the safety Follow-up Visit or [ADDRESS_245008] dose, and agrees to use a
condom with spermicide or abstain from heterosexual
intercourse during the study until 7 days after study drug
administration. (Note: No restrictions are required for a
vasectomized male provided his vasectomy was performed
2:4 months prior to dosing);
8.Has a dry body weight of 2:40.0 kg at screening (prescription
target dry body weight);
9.Has adequacy of dialysis, defined as meeting 1 of the following
criteria during the 3 months prior to screening:
a.2:2 single-pool Kt/V measurements 2: 1.2; or
b.urea reduction ratio measurements 2:65%; or
c.1 single-pool Kt/V measurement 2:1.2 and 1 urea
reduction ratio measurement 2:65%
10.For de novo patients only, has recorded up to [ADDRESS_245009] dose (including the score on Day 1 of dosing), and has
at least 1 of the NRS scores >4.
Amendment 1.2 